N2-(1-carboxyethyl)-2'Deoxyguanosine (CEdG) a Potential Biomarker for Diabetes

Completed · Not applicable

Conditions studied: Diabetes

In brief

The purpose of this study is to see if the CEdG assay can produce internally consistent results and initiate its validation as a biomarker for diabetes in humans.

Key facts

Study ID

NCT02065310

Run by

City of Hope Medical Center

People needed

26

Starts

2014-10-01

Expected to finish

2019-02-11

Last updated by the study team

2019-11-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 18 years of age or older
• Registered patient of City of Hope
• Documentation of a diagnosis of diabetes identified by the problem list in the patient's electronic health record

You may not qualify if…

• Current pregnancy
• An active diagnosis of cancer, as CEdG levels may potentially be affected by malignant processes

Where it is running

• City of Hope Medical Center — Duarte, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.